Federation des caisses Desjardins du Quebec Boosts Stake in ANI Pharmaceuticals, Inc. $ANIP

Federation des caisses Desjardins du Quebec raised its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 15.3% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 24,275 shares of the specialty pharmaceutical company's stock after purchasing an additional 3,225 shares during the period. Federation des caisses Desjardins du Quebec owned 0.11% of ANI Pharmaceuticals worth $1,626,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Principal Financial Group Inc. lifted its position in shares of ANI Pharmaceuticals by 68.3% during the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock valued at $10,565,000 after buying an additional 64,021 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in ANI Pharmaceuticals by 53.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock valued at $599,000 after purchasing an additional 3,112 shares in the last quarter. Invesco Ltd. lifted its holdings in ANI Pharmaceuticals by 1.0% during the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock valued at $13,361,000 after purchasing an additional 2,022 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of ANI Pharmaceuticals by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after purchasing an additional 2,220 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Trading Down 1.0%

ANIP traded down $1.02 during trading on Friday, reaching $97.71. The company had a trading volume of 210,857 shares, compared to its average volume of 466,511. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The business has a 50 day simple moving average of $79.52 and a 200-day simple moving average of $69.62. The stock has a market cap of $2.12 billion, a P/E ratio of -126.89 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the prior year, the firm posted $1.02 earnings per share. The business's revenue for the quarter was up 53.2% on a year-over-year basis. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ANIP. Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a "buy" rating in a research note on Monday. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. Piper Sandler restated an "overweight" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. HC Wainwright reaffirmed a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $88.25.

Insider Buying and Selling

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,988 shares of the company's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $90.44, for a total value of $4,792,234.72. Following the completion of the sale, the chief operating officer directly owned 431,920 shares in the company, valued at approximately $39,062,844.80. This represents a 10.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Matthew J. Leonard sold 2,528 shares of the firm's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $90.62, for a total transaction of $229,087.36. Following the completion of the sale, the director owned 6,864 shares in the company, valued at $622,015.68. This represents a 26.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 412,430 shares of company stock worth $36,357,886 over the last 90 days. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.